CompletedPhase 2NCT02715115

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Studying Rett syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Neuren Pharmaceuticals Limited
Principal Investigator
Daniel Glaze, MD, MD
Baylor College of Medicine
Intervention
NNZ-2566(drug)
Enrollment
82 enrolled
Eligibility
5-15 years · FEMALE
Timeline
20162017

Study locations (12)

Collaborators

rettsyndrome.org

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02715115 on ClinicalTrials.gov

Other trials for Rett syndrome

Additional recruiting or active studies for the same condition.

See all trials for Rett syndrome

← Back to all trials